Potential Use of Patient-Specific Induced Pluripotent Stem Cell for Liver Fibrosis Thalassemia Treatment Management

Thalassemia is the most common inherited single gene blood disease worldwide and present a significant health problem in world. Approximately, 1.5% of global populations (An estimated 80–90 million people) are carriers β-thalassemia. Around 5% Indonesia population thought to carry thalassemia gene. The globin imbalance β-thalassemia major causes hemolysis ineffective erythropoiesis which results anemia leading increases iron absorption. Furthermore, repeated transfusion long-term increased absorption will lead excessive accumulation vital organs, especially liver, liver fibrosis then disease. Iron overload can be controlled by chelating drugs with risk side effects; therefore, breakthrough needed. Stem cell technology has potential provide novel insight major, through induced pluripotent stem cells (iPSCs) who ability differentiate into hepatic stellate (HSCs)-like cells. iPSCs derived HSC-like (iPSC-HSCs) phenotypic functional characteristics HSCs. utilization new option personalized management.